Vor Biopharma Inc. Increase (Decrease) in Other Operating Assets
Vor Biopharma Inc. (VOR) reported Increase (Decrease) in Other Operating Assets of $27.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-11
- Vor Biopharma Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $7.00K.
- Vor Biopharma Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $20.00K.
- Vor Biopharma Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was $2.11M.
- Vor Biopharma Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$151.00K.
- Vor Biopharma Inc. increase (decrease) in other operating assets for fiscal 2025 was $0.00.
- Vor Biopharma Inc. increase (decrease) in other operating assets for fiscal 2024 was -$2.43M, a 228.72% decline from fiscal 2023.
- Vor Biopharma Inc. increase (decrease) in other operating assets for fiscal 2023 was $1.89M, a 161.72% increase from fiscal 2022.
- Vor Biopharma Inc. increase (decrease) in other operating assets for fiscal 2022 was $721.00K, a 7.93% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $27.00K 10-Q · filed 2026-08-11 | $2.14M derived: sum of 3 quarters · filed 2026-08-11 | $1.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-13 | $2.13M derived: sum of 2 quarters · filed 2026-05-13 | $1.98M derived: sum of 3 quarters · filed 2026-05-13 | $34.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.96M derived: sum of 2 quarters · filed 2026-03-30 | $14.00K derived: sum of 3 quarters · filed 2026-08-11 | $0.00 10-K · filed 2026-03-30 |
| 2025-09-30 | -$151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.10M derived: sum of 2 quarters · filed 2026-08-11 | -$2.11M 10-Q · filed 2025-11-13 | -$2.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.96M 10-Q · filed 2026-08-11 | -$2.09M derived: sum of 3 quarters · filed 2026-08-11 | -$2.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$14.00K 10-Q · filed 2026-05-13 | -$143.00K derived: sum of 2 quarters · filed 2026-05-13 | -$694.00K derived: sum of 3 quarters · filed 2026-05-13 | -$2.45M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$680.00K derived: sum of 2 quarters · filed 2026-03-30 | -$2.44M derived: sum of 3 quarters · filed 2026-03-30 | -$2.43M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$551.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.31M derived: sum of 2 quarters · filed 2025-11-13 | -$2.30M 10-Q · filed 2025-11-13 | -$1.57M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.75M 10-Q · filed 2025-08-12 | -$1.02M derived: sum of 3 quarters · filed 2025-08-12 | -$205.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $7.00K 10-Q · filed 2025-05-14 | $733.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.55M derived: sum of 3 quarters · filed 2025-05-14 | $2.03M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $726.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.54M derived: sum of 2 quarters · filed 2025-03-20 | $2.02M derived: sum of 3 quarters · filed 2025-03-20 | $1.89M 10-K · filed 2025-03-20 |
| 2023-09-30 | $818.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.29M derived: sum of 2 quarters · filed 2024-11-07 | $1.16M 10-Q · filed 2024-11-07 | $1.21M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $477.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $343.00K 10-Q · filed 2024-08-08 | $390.00K derived: sum of 3 quarters · filed 2024-08-08 | $883.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$134.00K 10-Q · filed 2024-05-09 | -$87.00K derived: sum of 2 quarters · filed 2024-05-09 | $406.00K derived: sum of 3 quarters · filed 2024-05-09 | $452.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $540.00K derived: sum of 2 quarters · filed 2024-03-20 | $586.00K derived: sum of 3 quarters · filed 2024-03-20 | $721.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $493.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $539.00K derived: sum of 2 quarters · filed 2023-11-07 | $674.00K 10-Q · filed 2023-11-07 | $1.03M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $181.00K 10-Q · filed 2023-08-10 | $534.00K derived: sum of 3 quarters · filed 2023-08-10 | $564.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $135.00K 10-Q · filed 2023-05-11 | $488.00K derived: sum of 2 quarters · filed 2023-05-11 | $518.00K derived: sum of 3 quarters · filed 2023-05-11 | $944.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $353.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $383.00K derived: sum of 2 quarters · filed 2023-03-23 | $809.00K derived: sum of 3 quarters · filed 2023-03-23 | $668.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $456.00K derived: sum of 2 quarters · filed 2022-11-10 | $315.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $426.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $285.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$141.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $2.50M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |